Skip to main
SGMO
SGMO logo

Sangamo Therapeutics (SGMO) Stock Forecast & Price Target

Sangamo Therapeutics (SGMO) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 31%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Sangamo Therapeutics is positioned positively due to the increased estimated value of its SIFTER/ZFP platform, particularly attributed to the neurology pipeline, which is now valued at $7 per share. The probability of success for the isa-vec program has been significantly raised to 85%, reflecting enhanced regulatory positioning, despite a cautious adjustment of revenues to account for collaboration value retention. Additionally, the company's commitment to sustainability and its focus on demonstrating positive outcomes in functional cures and lower system costs further strengthen its long-term growth outlook.

Bears say

Sangamo Therapeutics Inc. faces significant challenges that contribute to a negative outlook, primarily due to the unpredictability of future revenues and expenses, as well as its current non-revenue-generating status. The company reported a considerable net loss of $23 million, or $0.11 per share, while taking drastic measures such as a 40% workforce reduction and halting key pipeline projects, which raises concerns about its operational viability. Additionally, the potential risks associated with clinical program execution, regulatory approvals, and emerging competitive pressures further exacerbate the uncertainty surrounding Sangamo's financial future.

Sangamo Therapeutics (SGMO) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 31% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sangamo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sangamo Therapeutics (SGMO) Forecast

Analysts have given Sangamo Therapeutics (SGMO) a Buy based on their latest research and market trends.

According to 16 analysts, Sangamo Therapeutics (SGMO) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.66, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.66, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sangamo Therapeutics (SGMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.